Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets

被引：0
|
作者：
Gasparyan, Armen Yuri [1 ]
机构：
[1] Russells Hall Hosp, Dudley Grp NHS Fdn Trust, Dudley DY1 2HQ, W Midlands, England
来源：
CURRENT PHARMACEUTICAL DESIGN | 2012年 / 18卷 / 11期
关键词：
RHEUMATOID-ARTHRITIS; ACCELERATED ATHEROSCLEROSIS; ALPHA THERAPY; DISEASE; ANEURYSMS; STATINS;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1447 / 1449
页数：3
相关论文
共 50 条
  • [31] Obstructive sleep apnea and cardiovascular comorbidity: common pathophysiological mechanisms to cardiovascular disease
    Agaltsov, M. V.
    Drapkina, O. M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (04) : 594 - 605
  • [32] Mechanisms and pathophysiological significance of sterile inflammation during acetaminophen hepatotoxicity
    Jaeschke, Hartmut
    Ramachandran, Anup
    FOOD AND CHEMICAL TOXICOLOGY, 2020, 138
  • [33] Nuclear Receptors and Inflammation Control: Molecular Mechanisms and Pathophysiological Relevance
    Huang, Wendy
    Glass, Christopher K.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (08) : 1542 - 1549
  • [34] Hypertension, cardiovascular disease, and nocturia: a systematic review of the pathophysiological mechanisms
    Mitsuru Ohishi
    Takuro Kubozono
    Koji Higuchi
    Yuichi Akasaki
    Hypertension Research, 2021, 44 : 733 - 739
  • [35] Xanthine oxicloreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
    Berry, CE
    Hare, JM
    JOURNAL OF PHYSIOLOGY-LONDON, 2004, 555 (03): : 589 - 606
  • [36] Hypertension, cardiovascular disease, and nocturia: a systematic review of the pathophysiological mechanisms
    Ohishi, Mitsuru
    Kubozono, Takuro
    Higuchi, Koji
    Akasaki, Yuichi
    HYPERTENSION RESEARCH, 2021, 44 (07) : 733 - 739
  • [37] Targets and endpoints in ablation therapy for atrial fibrillation in the light of pathophysiological mechanisms
    Scholten, MF
    Thornton, AS
    Mekel, JM
    Jordaens, LJ
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2006, 15 (01) : 27 - 33
  • [38] Targets and endpoints in ablation therapy for atrial fibrillation in the light of pathophysiological mechanisms
    Marcoen F. Scholten
    Andrew S. Thornton
    Joris M. Mekel
    Luc J. Jordaens
    Journal of Interventional Cardiac Electrophysiology, 2006, 15 : 27 - 33
  • [39] Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
    Schmitz G.
    Orsó E.
    Clinical Research in Cardiology Supplements, 2015, 10 (Suppl 1) : 21 - 25
  • [40] Lipoprotein(a) and inflammation-pathophysiological links and clinical implications for cardiovascular disease
    Simantiris, Spyridon
    Antonopoulos, Alexios S.
    Papastamos, Charalampos
    Benetos, Georgios
    Koumallos, Nikolaos
    Tsioufis, Konstantinos
    Tousoulis, Dimitris
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (01) : 55 - 63
12345